Pipeline

Curasight is advancing a first-in-class radioligand therapy, uTREAT^®, targeting uPAR — the functional driver of invasion, angiogenesis, and metastasis across multiple solid tumors. A true pipeline-in-a-drug.

uTREAT^® is uniquely supported by precise one-to-one molecular imaging through uTRACE^® enabling patient selection, treatment personalization, and efficient clinical development. uTRACE^® serves as a companion diagnostic to identify eligible patients and guide therapy, while uTREAT^® delivers targeted radiation to uPAR-expressing cancer cells and their supportive microenvironment.

Curasight is pursuing a platform-based development strategy, enabling parallel clinical programs across selected aggressive solid tumors using a shared biological target. This approach supports efficient pipeline expansion, a shared safety database, and positions uTREAT^® as a pipeline-in-a-drug.